NEW YORK (GenomeWeb News) — Oligomerix said today that it has received a $323,000 grant from the National Institutes of Health's National Institute on Aging for research that could lead to diagnostic assays for Alzheimer's disease.
The New York, NY-based company plans to use the Small Business Innovation Research funding to develop a test that could monitor proteins in cerebrospinal fluid and plasma from AD patients. This research will be conducted by researchers at Columbia University Medical Center.
The company said that it will evaluate novel biomarkers by studying protein-protein interactions in search of new ways of diagnosing and monitoring AD.
"Our focus is to develop assays that can be used for drug discovery for AD," Oligomerix CEO James Moe said in a statement. "Any validated assays developed under this program for disease staging or definitive diagnosis of AD will be potential out-licensing opportunities for the company."